Positive for Emcure

* CDSCO has approved Novo Nordisk’s Wegovy (semaglutide) as the first and only GLP-1 therapy in India for adults with metabolic dysfunction-associated steatohepatitis (MASH)/fatty liver disease with moderate-to-advanced fibrosis, expanding its use beyond obesity management. * Positive for

: As the exclusive commercialization and distribution partner for Wegovy/semaglutide in India, Emcure is well placed to benefit from the expanded indication, which opens up a larger addressable patient market and strengthens its metabolic disease portfolio.